
KZR Stock Forecast & Price Target
KZR Analyst Ratings
Bulls say
Kezar Life Sciences is showing promising developments as the lifting of the partial clinical hold in autoimmune hepatitis (AIH) boosts investor confidence in the risk–benefit profile of its leading candidate, Zetomipzomib (KZR-616). The potential full removal of the clinical hold in lupus nephritis (LN) could significantly enhance the company’s commercial prospects and overall investment appeal. This advancement indicates a positive trajectory for Zetomipzomib, paving the way for increased clinical uptake and broader market opportunities if further approvals are secured.
Bears say
Kezar Life Sciences Inc is facing significant financial challenges, evidenced by a widening net loss reported in the latest quarter, which indicates higher operational costs that could strain cash reserves. Additionally, the company has limited revenue generation to date, primarily reliant on funding from equity offerings to support its clinical pipeline, raising concerns about long-term sustainability. Moreover, delays in clinical trial progress for its key product candidates may hinder potential milestones and negatively impact investor confidence.
This aggregate rating is based on analysts' research of Kezar Life Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.
KZR Analyst Forecast & Price Prediction
Start investing in KZR
Order type
Buy in
Order amount
Est. shares
0 shares